文献速递肾癌与肾肿瘤

转移性肾细胞癌一线治疗:系统综述与网络Meta分析

First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
PubMed 文献 · Eur Urol Oncol · 2019-10-04

该系统综述与网络Meta分析纳入12项平行组随机对照试验,间接比较转移性肾细胞癌一线治疗的疗效与安全性。在ITT人群中,卡博替尼、阿维鲁单抗联合阿昔替尼和帕博利珠单抗联合阿昔替尼在PFS上优于其他药物,帕博利珠单抗联合阿昔替尼在OS上可能更优,阿替利珠单抗不良事件可能性最低。

要点

  • 帕博利珠单抗联合阿昔替尼和卡博替尼是多数mRCC患者的良好选择。
  • 阿替利珠单抗显示最低的不良事件可能性(SUCRA 100%)。
  • 在 favorable-risk 疾病中,阿维鲁单抗联合阿昔替尼可能更受青睐。

核心结论

  • mRCC最佳一线治疗可能因疗效终点、毒性和临床风险组而异。
  • 直接比较研究对于指导治疗选择仍然重要。

研究设计与样本

  • 系统综述与网络Meta分析,检索数据库自建库至2019年2月17日。
  • 纳入12项平行组随机对照试验,评估mRCC一线治疗。
  • 12项报告PFS,9项报告OS,10项报告ORR,9项报告不良事件。

主要发现

  • ITT人群中,卡博替尼(SUCRA 84%)、阿维鲁单抗联合阿昔替尼(SUCRA 68%)和帕博利珠单抗联合阿昔替尼(SUCRA 82%)在PFS上优于其他药物。
  • 帕博利珠单抗联合阿昔替尼在OS上似乎更优(SUCRA 95%)。
  • 阿替利珠单抗显示最低的不良事件可能性(SUCRA 100%)。
  • 在 intermediate/poor-risk 亚组中结果相似。
  • 基于有限数据,阿维鲁单抗联合阿昔替尼可能在 favorable-risk 疾病中更受青睐。

关键数值与推荐

  • PFS为主要结局,OS、ORR和3/4级不良事件为次要结局。
  • 卡博替尼PFS SUCRA 84%,阿维鲁单抗联合阿昔替尼SUCRA 68%,帕博利珠单抗联合阿昔替尼SUCRA 82%。
  • 帕博利珠单抗联合阿昔替尼OS SUCRA 95%。
  • 阿替利珠单抗不良事件SUCRA 100%。

临床怎么用

  • 对于多数mRCC患者,帕博利珠单抗联合阿昔替尼和卡博替尼可作为良好的一线选择。
  • 临床决策需综合考虑疗效终点、毒性和临床风险组。
  • favorable-risk患者可考虑阿维鲁单抗联合阿昔替尼。

局限性

  • 无头对头临床试验比较当代一线治疗。
  • 网络Meta分析为间接比较。
  • favorable-risk亚组数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: No head-to-head clinical trials compare contemporary first-line therapies for metastatic renal cell carcinoma (mRCC). A network meta-analysis provides an approach for quantitative analysis. OBJECTIVE: To indirectly compare the efficacy and safety of first-line treatments for mRCC in the intention-to-treat (ITT) population and by clinical risk group. EVIDENCE ACQUISITION: An updated systematic review from database inception to February 17, 2019 identified all parallel-group randomized controlled trials assessing first-line therapy for mRCC. "Clinically relevant" studies were selected for a network meta-analysis. Progression-free survival (PFS) was the primary outcome. Overall survival (OS), overall response rate (ORR), and grade 3 and 4 adverse events (AEs) were secondary outcomes. EVIDENCE SYNTHESIS: We identified 12 relevant trials: 12 reported outcomes for PFS, nine for OS, 10 for ORR, and nine for AEs. In the ITT population, cabozantinib (surface under the cumulative ranking curves [SUCRA] 84%), avelumab plus axitinib (SUCRA 68%), and pembrolizumab plus axitinib (SUCRA 82%) were superior to the other agents for PFS; pembrolizumab plus axitinib appeared superior for OS (SUCRA 95%); and atezolizumab demonstrated the lowest likelihood of AEs (SUCRA 100%). Findings were similar in the intermediate/poor-risk subgroup. Based on the limited data available, avelumab plus axitinib may be preferred in patients with favorable-risk disease. CONCLUSIONS: The optimal first-line treatment for mRCC appears to differ by efficacy endpoint, toxicity, and clinical risk group. Direct comparative studies remain important in guiding treatment choice. PATIENT SUMMARY: Head-to-head comparisons do not exist for the newest treatments of metastatic renal cell carcinoma (mRCC). In an indirect comparison, we found that pembrolizumab plus axitinib and cabozantinib are good options for most patients with mRCC.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Hahn AW, Klaassen Z, Agarwal N, et al. First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. Eur Urol Oncol. 2019. PMID: 31588018. doi:10.1016/j.euo.2019.09.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。